The estimated Net Worth of Robert J. Shovlin is at least $14.5 Million dollars as of 25 May 2021. Mr. Shovlin owns over 130,604 units of Neogenomics stock worth over $2,448,147 and over the last 10 years he sold NEO stock worth over $10,774,218. In addition, he makes $1,284,100 as President - Clinical Services Division at Neogenomics.
Sign up
Mr. Shovlin NEO stock SEC Form 4 insiders trading
Robert has made over 10 trades of the Neogenomics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 130,604 units of NEO stock worth $5,134,043 on 25 May 2021.
The largest trade he's ever made was exercising 300,000 units of Neogenomics stock on 9 November 2018 worth over $1,437,000. On average, Robert trades about 54,393 units every 100 days since 2014. As of 25 May 2021 he still owns at least 150,101 units of Neogenomics stock.
You can see the complete history of Mr. Shovlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Shovlin biography
Robert J. Shovlin serves as President - Clinical Services Division of the Company. Mr. Shovlin has served as the President of our Clinical Services Division since September, 2016. Prior to this, he had served as our Chief Growth Officer since the acquisition of Clarient Inc. (“Clarient”) in 2015. From his hire date in October 2014 until the Clarient acquisition, Mr. Shovlin served as the Chief Operating Officer of NeoGenomics. From 2012 until October 2014, Mr. Shovlin served as Chief Development officer for Bostwick Laboratories, a provider of anatomic pathology testing services targeting urologists and other clinicians, where he was responsible for Sales, Marketing, Managed Care, Business Development, and Clinical Trials. From 2005 until 2011, he served in progressively more responsible positions, including President and Chief Executive Officer, for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director for Anatomic Pathology and Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer in the United States Marine Corps from 1992 until 1997 where he served as a Platoon and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at the Basic School. He holds a Bachelor of Science Degree from Pennsylvania State University, and a Masters of Business Administration from Rutgers University.
What is the salary of Robert Shovlin?
As the President - Clinical Services Division of Neogenomics, the total compensation of Robert Shovlin at Neogenomics is $1,284,100. There are 1 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
How old is Robert Shovlin?
Robert Shovlin is 49, he's been the President - Clinical Services Division of Neogenomics since 2016. There are 20 older and 5 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
What's Robert Shovlin's mailing address?
Robert's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Insiders trading at Neogenomics
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, and Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
What does Neogenomics do?
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
What does Neogenomics's logo look like?
Complete history of Mr. Shovlin stock trades at Neogenomics
Neogenomics executives and stock owners
Neogenomics executives and other stock owners filed with the SEC include:
-
Douglas VanOort,
Chairman of the Board, Chief Executive Officer -
Robert Shovlin,
President - Clinical Services Division -
Lawrence Weiss,
Chief Medical Officer -
George Cardoza,
President - Pharma Services Division -
William Bonello,
President, Informatics and Director of Investor Relations -
Douglas M. Brown,
Chief Strategy & Corp. Devel. Officer -
Kathryn McKenzie,
Chief Financial Officer -
Steven Ross,
Chief Information Officer -
Steven Jones,
Director -
Alison Hannah,
Independent Director -
Lynn Tetrault,
Lead Independent Director -
Raymond Hipp,
Independent Director -
Bruce Crowther,
Independent Director -
Kevin Johnson,
Independent Director -
Stephen Kanovsky,
Independent Director -
Michael Kelly,
Independent Director -
Rachel Stahler,
Director -
Douglas Brown,
Chief Strategy and Corporate Development Officer -
Denise Pedulla,
General Counsel, Corporate Secretary -
Jennifer Balliet,
Vice President, Chief Culture Officer -
Stephanie Bywater,
Chief Compliance Officer -
Cynthia Dieter,
Chief Accounting Officer, Controller -
Dr. Steven G. Brodie FACMG, Ph.D.,
Sr. VP of Laboratory Operations -
George A. Cardoza,
Pres & COO of Lab Operations -
Marcus B. Silva J.D., M.B.A.,
Chief Marketing Officer -
Halley E. Gilbert Esq., J.D.,
Chief Legal Officer -
Charlie Eidson,
Director of Investor Relations and Corp. Devel. -
John Mooney,
Chief Technology Officer -
Cynthia J. Dieter,
Chief Accounting Officer & Controller -
Mark W. Mallon,
CEO & Director -
William J Robison,
Director -
Maher Albitar,
Chief Medical Officer -
Sharon Virag,
Chief Financial Officer -
David Sholehvar,
President, Clinical Services -
Neil Gunn,
Director -
Elizabeth Floegel,
Director -
Anthony P. Zook,
Director -
Christopher M Smith,
Chief Executive Officer -
Mark Alan Machulcz,
Vice President of Operations -
Michael T Dent,
Director -
Steven G. Brodie,
Chief Scientific Officer -
Steven Caspen Select Health...,
Executive VP of FinanceExecutive VP of Finance -
Robert H. Horel,
Vice President andGM PathLogic -
Robert P Gasparini,
Chief Science Officer -
Halley E Gilbert,
Chief Legal Officer -
Gina M Wallar,
President, Pharma Services -
Mark Mallon,
Chief Executive Officer -
Clive Morris,
President of Inivata -
Oort Douglas M Van,
Director -
David Daly,
Director -
Vishal Sikri,
President Advanced Diagnostics -
David Brian Perez,
Director -
Jeffrey Scott Sherman,
Chief Financial Officer -
Shashikant Kulkarni,
Chief Scientific Officer -
Alicia C Olivo,
General Counsel -
Melody Harris,
Chf Ops Off, Pres, Informatics -
Greg D Aunan,
Chief Accounting Officer -
Warren Stone,
Chief Commerical Officer